Revolutionizing Cancer Treatment: The Impact of Stem Cell Transplants at Community Health Network MD Anderson Cancer Center

At Community Health Network’s MD Anderson Cancer Center, a groundbreaking milestone has been reached with the center’s first stem cell transplant. This significant medical advancement involves the infusion of a patient’s own stem cells, which were harvested, frozen, and reintroduced after a high dose of chemotherapy. The procedure aims to restore the bone marrow and […]
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy

HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen […]